DELIVER-HF Dapagliflozin Benefit Calculator
Estimate treatment benefit
Enter patient characteristics to calculate the source model's illustrative 2-year estimates.
About the DELIVER trial
DELIVER evaluated dapagliflozin 10 mg once daily versus placebo, added to usual therapy, in patients with heart failure and LVEF greater than 40%. The primary endpoint was worsening heart failure (unplanned hospitalization or an urgent visit for heart failure) or cardiovascular death.
Published trial results
| Outcome | Dapagliflozin | Placebo |
|---|---|---|
| Primary endpoint over median 2.3 years | 16.4% | 19.5% |
| Hazard ratio (95% CI) | 0.82 (0.73–0.92) | |
The trial-level event rates above are observed study results; they should not be interpreted as an individual's untreated baseline risk. The trial's hazard ratio also does not validate the adjustment formula used by this calculator.
What this calculator does
- Starts with an assumed 20% 2-year baseline risk.
- Applies the original source file's simplified adjustments for NT-proBNP, eGFR below 60, and NYHA class III/IV.
- Caps the estimated baseline risk at 50% and applies an assumed treatment HR of 0.82 to derive nominal ARR and NNT.
Limitations and clinical use
- This is a non-validated illustrative model, not a DELIVER-derived individual risk equation.
- Age and LVEF are used for input eligibility checks but do not change the numerical estimate.
- The formula does not incorporate all clinical variables, competing risks, follow-up differences, or uncertainty around the treatment effect.
- The calculated NNT is sensitive to the assumed baseline risk and should not be treated as a trial-reported NNT.
Reference
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.